Neos Therapeutics, Inc. today announced that it will report third quarter 2018 financial results prior to the opening of U.S. financial markets on Friday, November 9, 2018.
DALLAS and FORT WORTH, Texas, , Nov. 02, 2018 (GLOBE NEWSWIRE) -- NEOS Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will report third quarter 2018 financial results prior to the opening of U.S. financial markets on Friday, November 9, 2018. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.
The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 6737227. A live audio webcast for the conference call will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ: NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are three approved products using the Company’s extended-release technology platform. Additional information about Neos is available at www.neostx.com.
CONTACTS:
Richard I. Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
Sarah McCabe and Carl Mauch
Investor Relations
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com and carl@sternir.com
Neos Therapeutics, Inc.
